They have tried to justify their negative observation as consequence of inclusion criteria (i.e., included patients were not limited to proximal LAD occlusion alone), species differences in EPO response, effective dose, reperfusion-EPO infusion therapeutic window (time), and MI sequel evaluation methods (i.e., echocardiography vs. cardiac magnetic resonance imaging, to evaluate infarct size, ejection fraction, and LV function) (Prunier et al., 2007, 2012; Huang et al., 2008; Najjar et al., 2011; Talan et al., 2012; Roubille et al., 2013a,b). The gene discussed is EPO; the disease is myocardial infarction.